-
公开(公告)号：US10239829B2
公开(公告)日：2019-03-26
申请号：US15614418
申请日：2017-06-05
发明人： Jorge E. Gomez-Galeno , Raja K. Reddy , Paul D. van Poelje , Robert Huerta Lemus , Thanh Huu Nguyen , Matthew P. Grote , Qun Dang , Scott J. Hecker , Venkat Reddy Mali , Mingwei Chen , Zhili Sun , Serge Henri Boyer , Haiqing Li , William Craigo
IPC分类号： C07C309/15 , C07C317/44 , C07C323/62 , C07D209/20 , C07D213/53 , C07D213/75 , C07D235/30 , C07D261/08 , C07D263/56 , C07C309/11 , C07D307/68 , C07D307/81 , C07D317/66 , C07D333/38 , C07D405/04 , C07D409/12 , C07D413/04 , C07D471/04 , C07D498/04 , C07C307/02 , C07D277/66
摘要： The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
-
公开(公告)号：US09169201B2
公开(公告)日：2015-10-27
申请号：US14147457
申请日：2014-01-03
发明人： Jorge E. Gomez-Galeno , Raja K. Reddy , Paul D. van Poelje , Robert Huerta Lemus , Thanh Huu Nguyen , Matthew P. Grote , Qun Dang , Scott J. Hecker , Venkat Reddy Mali , Mingwei Chen , Zhili Sun , Serge Henri Boyer , Haiqing Li , William Craigo
IPC分类号： C07C307/02 , C07C309/11 , C07C309/15 , C07C317/44 , C07C323/62 , C07D209/20 , C07D213/53 , C07D213/75 , C07D235/30 , C07D261/08 , C07D263/56 , C07D277/66 , C07D307/68 , C07D307/81 , C07D317/66 , C07D333/38 , C07D405/04 , C07D409/12 , C07D413/04 , C07D471/04 , C07D498/04
CPC分类号： C07C309/15 , C07C307/02 , C07C309/11 , C07C317/44 , C07C323/62 , C07C2601/02 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07C2602/10 , C07C2603/74 , C07D209/20 , C07D213/53 , C07D213/75 , C07D235/30 , C07D261/08 , C07D263/56 , C07D277/66 , C07D307/68 , C07D307/81 , C07D317/66 , C07D333/38 , C07D405/04 , C07D409/12 , C07D413/04 , C07D471/04 , C07D498/04
摘要： The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
摘要翻译： 本发明提供具有胰高血糖素受体拮抗剂或反向激动剂活性的新颖的式（I）化合物及其药学上可接受的盐和共晶体。 本发明进一步提供了包含其的药物组合物以及治疗，预防，延迟发病时间或降低其中指示一种或多种胰高血糖素受体拮抗剂的疾病或病症的发展或进展的风险的方法， 包括I型和II型糖尿病，胰岛素抵抗和高血糖。 本发明还提供制备式I化合物的方法，包括其盐和共结晶，以及包含其的药物组合物。
-
公开(公告)号：US10807946B2
公开(公告)日：2020-10-20
申请号：US16363825
申请日：2019-03-25
发明人： Jorge E. Gomez-Galeno , Raja K. Reddy , Paul D. Van Poelje , Robert Huerta Lemus , Thanh Huu Nguyen , Matthew P. Grote , Qun Dang , Scott J. Hecker , Venkat Reddy Mali , Mingwei Chen , Zhili Sun , Serge Henri Boyer , Haiqing Li , William Craigo
IPC分类号： C07C309/15 , C07D317/66 , C07C309/11 , C07C317/44 , C07C323/62 , C07D209/20 , C07D213/53 , C07D498/04 , C07D471/04 , C07D413/04 , C07D409/12 , C07D405/04 , C07D333/38 , C07C307/02 , C07D307/81 , C07D307/68 , C07D277/66 , C07D263/56 , C07D261/08 , C07D235/30 , C07D213/75
摘要： The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof and pharmaceutical compositions comprising the same.
-
公开(公告)号：US20160009639A1
公开(公告)日：2016-01-14
申请号：US14860593
申请日：2015-09-21
发明人： Jorge E. Gomez-Galeno , Raja K. Reddy , Paul D. van Poelje , Robert Huerta Lemus , Thanh Huu Nguyen , Matthew P. Grote , Qun Dang , Scott J. Hecker , Venkat Reddy Mali , Mingwei Chen , Zhili Sun , Serge Henri Boyer , Haiqing Li , William Craigo
IPC分类号： C07C309/15
CPC分类号： C07C309/15 , C07C307/02 , C07C309/11 , C07C317/44 , C07C323/62 , C07C2601/02 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07C2602/10 , C07C2603/74 , C07D209/20 , C07D213/53 , C07D213/75 , C07D235/30 , C07D261/08 , C07D263/56 , C07D277/66 , C07D307/68 , C07D307/81 , C07D317/66 , C07D333/38 , C07D405/04 , C07D409/12 , C07D413/04 , C07D471/04 , C07D498/04
摘要： The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
摘要翻译： 本发明提供具有胰高血糖素受体拮抗剂或反向激动剂活性的新颖的式（I）化合物及其药学上可接受的盐和共晶体。 本发明进一步提供了包含其的药物组合物以及治疗，预防，延迟发病时间或降低其中指示一种或多种胰高血糖素受体拮抗剂的疾病或病症的发展或进展的风险的方法， 包括I型和II型糖尿病，胰岛素抵抗和高血糖。 本发明还提供制备式I化合物的方法，包括其盐和共结晶，以及包含其的药物组合物。
-
公开(公告)号：US20190218176A1
公开(公告)日：2019-07-18
申请号：US16363825
申请日：2019-03-25
发明人： Jorge E. GOMEZ-GALENO , Raja K. Reddy , Paul D. Van Poelje , Robert Huerta Lemus , Thanh Huu Nguyen , Matthew P. Grote , Qun Dang , Scott J. Hecker , Venkat Reddy Mali , Mingwei Chen , Zhili Sun , Serge Henri Boyer , Haiqing Li , William Craigo
IPC分类号： C07C309/15 , C07D317/66 , C07C309/11 , C07C317/44 , C07C323/62 , C07D209/20 , C07D213/53 , C07D498/04 , C07D471/04 , C07D413/04 , C07D409/12 , C07D405/04 , C07D333/38 , C07C307/02 , C07D307/81 , C07D307/68 , C07D277/66 , C07D263/56 , C07D261/08 , C07D235/30 , C07D213/75
摘要： The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof and pharmaceutical compositions comprising the same.
-
公开(公告)号：US20170275246A1
公开(公告)日：2017-09-28
申请号：US15614418
申请日：2017-06-05
发明人： Jorge E. Gomez-Galeno , Raja K. Reddy , Paul D. van Poelje , Robert Huerta Lemus , Thanh Huu Nguyen , Matthew P. Grote , Qun Dang , Scott J. Hecker , Venkat Reddy Mali , Mingwei Chen , Zhili Sun , Serge Henri Boyer , Haiqing Li , William Craigo
IPC分类号： C07C309/15 , C07C317/44 , C07C323/62 , C07D209/20 , C07D213/53 , C07D213/75 , C07D235/30 , C07D261/08 , C07D263/56 , C07C309/11 , C07D307/68 , C07D307/81 , C07D317/66 , C07D333/38 , C07D405/04 , C07D409/12 , C07D413/04 , C07D471/04 , C07D498/04 , C07C307/02 , C07D277/66
CPC分类号： C07C309/15 , C07C307/02 , C07C309/11 , C07C317/44 , C07C323/62 , C07C2601/02 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07C2602/10 , C07C2603/74 , C07D209/20 , C07D213/53 , C07D213/75 , C07D235/30 , C07D261/08 , C07D263/56 , C07D277/66 , C07D307/68 , C07D307/81 , C07D317/66 , C07D333/38 , C07D405/04 , C07D409/12 , C07D413/04 , C07D471/04 , C07D498/04
摘要： The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
-
公开(公告)号：US09701626B2
公开(公告)日：2017-07-11
申请号：US14860593
申请日：2015-09-21
发明人： Jorge E. Gomez-Galeno , Raja K. Reddy , Paul D. van Poelje , Robert Huerta Lemus , Thanh Huu Nguyen , Matthew P. Grote , Qun Dang , Scott J. Hecker , Venkat Reddy Mali , Mingwei Chen , Zhili Sun , Serge Henri Boyer , Haiqing Li , William Craigo
IPC分类号： C07C309/15 , C07C307/02 , C07C309/11 , C07C317/44 , C07C323/62 , C07D209/20 , C07D213/53 , C07D213/75 , C07D235/30 , C07D261/08 , C07D263/56 , C07D277/66 , C07D307/68 , C07D307/81 , C07D317/66 , C07D333/38 , C07D405/04 , C07D409/12 , C07D413/04 , C07D471/04 , C07D498/04
CPC分类号： C07C309/15 , C07C307/02 , C07C309/11 , C07C317/44 , C07C323/62 , C07C2601/02 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07C2602/10 , C07C2603/74 , C07D209/20 , C07D213/53 , C07D213/75 , C07D235/30 , C07D261/08 , C07D263/56 , C07D277/66 , C07D307/68 , C07D307/81 , C07D317/66 , C07D333/38 , C07D405/04 , C07D409/12 , C07D413/04 , C07D471/04 , C07D498/04
摘要： The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
-
公开(公告)号：US20140135400A1
公开(公告)日：2014-05-15
申请号：US14147457
申请日：2014-01-03
发明人： Jorge E. Gomez-Galeno , Raja K. Reddy , Paul D. van Poelje , Robert Huerta Lemus , Thanh Huu Nguyen , Matthew P. Grote , Qun Dang , Scott J. Hecker , Venkat Reddy Mali , Mingwei Chen , Zhili Sun , Serge Henri Boyer , Haiqing Li , William Craigo
IPC分类号： C07C309/15
CPC分类号： C07C309/15 , C07C307/02 , C07C309/11 , C07C317/44 , C07C323/62 , C07C2601/02 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07C2602/10 , C07C2603/74 , C07D209/20 , C07D213/53 , C07D213/75 , C07D235/30 , C07D261/08 , C07D263/56 , C07D277/66 , C07D307/68 , C07D307/81 , C07D317/66 , C07D333/38 , C07D405/04 , C07D409/12 , C07D413/04 , C07D471/04 , C07D498/04
摘要： The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
摘要翻译： 本发明提供具有胰高血糖素受体拮抗剂或反向激动剂活性的新颖的式（I）化合物及其药学上可接受的盐和共晶体。 本发明进一步提供了包含其的药物组合物以及治疗，预防，延迟发病时间或降低其中指示一种或多种胰高血糖素受体拮抗剂的疾病或病症的发展或进展的风险的方法， 包括I型和II型糖尿病，胰岛素抵抗和高血糖。 本发明还提供制备式I化合物的方法，包括其盐和共结晶，以及包含其的药物组合物。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.06 秒)
